6 Jun 2019 09:52
Collagen Solutions Plc
(the "Company")
Director/PDMR Dealing
Collagen Solutions plc (AIM:COS), the developer and manufacturer of biomaterials and regenerative medicines for the enhancement and extension of human life, is pleased to announce that, further to its announcements on 20 May 2019 and 5 June 2019 in connection with the Strategic Investment, Placing and Open Offer, the following Directors/PDMRs have acquired Shares at the Offer Price in the following amounts.
Director/PDMR | Position | Existing Ordinary Shares held | Shares subscribed for at Offer Price | Aggregate price paid for Shares | Number of Ordinary Shares held following Admission |
|
|
|
|
|
|
Malcolm Gillies | Non-Executive Director | 4,153,000 | 847,000 | £42,350 | 5,000,000 |
Hilary Spence | Chief Financial Officer | 250,817 | 300,000 | £15,000 | 550,817 |
Tom Hyland | Chief Operating Officer | 273,847 | 200,000 | £10,000 | 473,847 |
Gillian Black | Company Secretary | 857,143 | 150,000 | £7,500 | 1,007,143 |
|
|
|
|
|
|
Unless otherwise defined, capitalised terms shall have the same meaning as defined in the circular posted to Shareholders on 20 May 2019, which is available to view on the Company's website at www.collagensolutions.com
The Company makes the following disclosures in accordance with article 19(3) of the Market Abuse Regulations
1
| Details of the person discharging managerial responsibilities / person closely associated
| |||||||||||
a)
| Name
| 1. Malcolm Gillies 2. Hilary Spence 3. Tom Hyland 4. Gillian Black
| ||||||||||
2
| Reason for the notification
| |||||||||||
a)
| Position/status
| 1. Non-Executive Director 2. Chief Financial Officer 3. Chief Operating Officer 4. Company Secretary | ||||||||||
b)
| Initial notification /Amendment
| Initial | ||||||||||
3
| Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
| |||||||||||
a)
| Name
| Collagen Solutions plc | ||||||||||
b)
| LEI
| 213800IFY1CVGRGETL95 | ||||||||||
4
| Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
| |||||||||||
a)
| Description of the financial instrument, type of instrument
Identification code
| New ordinary shares of 1p each
ISIN: GB00B94T6Y14
| ||||||||||
b)
| Nature of the transaction
| Acquisition of new ordinary shares pursuant to placing, open offer and subscription | ||||||||||
c)
| Price(s) and volume(s)
|
| ||||||||||
d)
| Aggregated information
- Aggregated volume
- Price
|
N/A - single transactions
| ||||||||||
e)
| Date of the transaction
| 6 June 2019 | ||||||||||
f)
| Place of the transaction
| London Stock Exchange | ||||||||||
Enquiries:
Collagen Solutions Plc | Contact via Walbrook | ||
Jamal Rushdy, CEO |
| ||
Hilary Spence, CFO |
| ||
|
| ||
Cenkos Securities plc (Nominated Adviser and Broker) Giles Balleny / Stephen Keys | Tel: 0207 397 8900
| ||
|
| ||
Walbrook PR Ltd | Tel: 020 7933 8780 or collagen@walbrookpr.com | ||
Anna Dunphy | Mob: 07876 741 001 | ||